Meiji Seika Kaisha Ltd.

Patent No. 7,595,182 Issued on Sept. 29, Assigned to Meiji Seika Kaisha for Endoglucanase Derived (Japanese Inventors)
US Fed News Service, Including US State News; 10/3/2009; 408 words; ...derived. The inventors were issued U.S. Patent No. 7,595,182 on Sept. 29. The patent has been assigned to Meiji Seika Kaisha Ltd., Tokyo. According to the abstract released by the U.S. Patent & Trademark Office: "A novel endoglucanase...

Research from Meiji Seika Kaisha, Ltd. reveals new findings on anxiety disorders.
Biotech Week; 9/9/2009; 1145 words; ...Yokoyama and colleagues, Meiji Seika Kaisha, Ltd.. The researchers concluded...information, contact N. Kakui, Meiji Seika Kaisha Ltd, Pharmaceutical Research...Inhibitors, Therapy, Treatment, Meiji Seika Kaisha, Ltd.. This article was ...

Publication No. WO/2009/104622 Published on Aug. 27, Assigned to Meiji Seika Kaisha for Thermotolerant Catalase (Japanese Inventors)
US Fed News Service, Including US State News; 9/1/2009; 457 words; ...Koichiro Murashima, all from Japan, have developed a thermotolerant catalase. The patent has been assigned to Meiji Seika Kaisha Ltd., Tokyo. According to an abstract posted by the World Intellectual Property Organization, the object aims to...

Other News To Note.
BIOWORLD Today; 8/25/2009; 1799 words; ...opportunistic infections). Celentyx Ltd., of Birmingham, UK, said it...a drug reprofiling agreement with Meiji Seika Kaisha Ltd., of Tokyo, aimed at seeking alternative...deprioritized for reasons other than safety. Meiji will use Celentyx's Novel Clinical...

Japan: Celentyx Signs Drug Reprofiling Agreement With.
TendersInfo; 8/25/2009; 464 words; ...profiling agreement with Meiji Seika Kaisha. Celentyx will use its...discontinued or sidelined by Meiji for reasons other than...particularly pleased to add Meiji as a partner, since they...Euclid Infotech Pvt. Ltd. Provided by Syndigate...